Literature DB >> 28586331

Viral vanguard: Designing cancer-killing viruses to chase metastatic tumors.

Shraddha Chakradhar.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28586331     DOI： 10.1038/nm0617-652

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  7 in total

1.  Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus.

Authors:  D F Stojdl; B Lichty; S Knowles; R Marius; H Atkins; N Sonenberg; J C Bell
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

Review 2.  History of oncolytic viruses: genesis to genetic engineering.

Authors:  Elizabeth Kelly; Stephen J Russell
Journal:  Mol Ther       Date:  2007-02-13       Impact factor: 11.454

3.  ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.

Authors:  B L Liu; M Robinson; Z-Q Han; R H Branston; C English; P Reay; Y McGrath; S K Thomas; M Thornton; P Bullock; C A Love; R S Coffin
Journal:  Gene Ther       Date:  2003-02       Impact factor: 5.250

4.  Maraba virus as a potent oncolytic vaccine vector.

Authors:  Jonathan G Pol; Liang Zhang; Byram W Bridle; Kyle B Stephenson; Julien Rességuier; Stephen Hanson; Lan Chen; Natasha Kazdhan; Jonathan L Bramson; David F Stojdl; Yonghong Wan; Brian D Lichty
Journal:  Mol Ther       Date:  2013-10-25       Impact factor: 11.454

5.  Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.

Authors:  Nalini Marino; Sam Illingworth; Prithvi Kodialbail; Ashvin Patel; Hugo Calderon; Rochelle Lear; Kerry D Fisher; Brian R Champion; Alice C N Brown
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

6.  Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood.

Authors:  Y Di; L Seymour; K Fisher
Journal:  Gene Ther       Date:  2014-02-20       Impact factor: 5.250

7.  Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial.

Authors:  Robert H I Andtbacka; Merrick Ross; Igor Puzanov; Mohammed Milhem; Frances Collichio; Keith A Delman; Thomas Amatruda; Jonathan S Zager; Lee Cranmer; Eddy Hsueh; Lisa Chen; Mark Shilkrut; Howard L Kaufman
Journal:  Ann Surg Oncol       Date:  2016-06-24       Impact factor: 5.344
  7 in total
  5 in total

Review 1.  Targeted and Immune-Based Therapies for Hepatocellular Carcinoma.

Authors:  Tim F Greten; Chunwei Walter Lai; Guangfu Li; Kevin F Staveley-O'Carroll
Journal:  Gastroenterology       Date:  2018-10-01       Impact factor: 22.682

Review 2.  Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders.

Authors:  Alireza Shahryari; Marie Saghaeian Jazi; Saeed Mohammadi; Hadi Razavi Nikoo; Zahra Nazari; Elaheh Sadat Hosseini; Ingo Burtscher; Seyed Javad Mowla; Heiko Lickert
Journal:  Front Genet       Date:  2019-09-25       Impact factor: 4.599

3.  Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.

Authors:  José Medina-Echeverz; Maria Hinterberger; Marco Testori; Marlene Geiger; Raphael Giessel; Barbara Bathke; Ronny Kassub; Fabienne Gräbnitz; Giovanna Fiore; Sonia T Wennier; Paul Chaplin; Mark Suter; Hubertus Hochrein; Henning Lauterbach
Journal:  Nat Commun       Date:  2019-11-06       Impact factor: 14.919

Review 4.  Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.

Authors:  Dirk M Nettelbeck; Mathias F Leber; Jennifer Altomonte; Assia Angelova; Julia Beil; Susanne Berchtold; Maike Delic; Jürgen Eberle; Anja Ehrhardt; Christine E Engeland; Henry Fechner; Karsten Geletneky; Katrin Goepfert; Per Sonne Holm; Stefan Kochanek; Florian Kreppel; Lea Krutzke; Florian Kühnel; Karl Sebastian Lang; Antonio Marchini; Markus Moehler; Michael D Mühlebach; Ulrike Naumann; Roman Nawroth; Jürg Nüesch; Jean Rommelaere; Ulrich M Lauer; Guy Ungerechts
Journal:  Viruses       Date:  2021-07-21       Impact factor: 5.048

Review 5.  Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors.

Authors:  Chang-Myung Oh; Hong Jae Chon; Chan Kim
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.